Gut Microbiota Dysbiosis as Risk and Premorbid Factors of IBD and IBS Along the Childhood-Adulthood Transition

Inflammatory Bowel Diseases

Volumn 22, Issue 2, 2016, Pages 487-504

  Putignani, Lorenza ^a   Del Chierico, Federica ^a   Vernocchi, Pamela ^a   Cicala, Michele ^b   Cucchiara, Salvatore ^c   Dallapiccola, Bruno ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

omics, meta omics, and microbial biomarkers; dysbiosis tracking; gastrointestinal disease predictors; gut microbiota dysbiosis scale; microbial community ecology

Indexed keywords

BIOLOGICAL MARKER;

ADULT; CHILD; CONSULTATION; DECISION SUPPORT SYSTEM; DIETARY INTAKE; DYSBIOSIS; FEEDING BEHAVIOR; GENETIC ASSOCIATION; GENOTYPE; HOMEOSTASIS; HUMAN; HYGIENE HYPOTHESIS; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; KNOWLEDGE MANAGEMENT; LABORATORY DIAGNOSIS; LIFESTYLE MODIFICATION; METAGENOMICS; MODULATION; NONHUMAN; ORGANISMAL INTERACTION; PHENOTYPE; PRIORITY JOURNAL; PROPHYLAXIS; RECURRENT DISEASE; REVIEW; RISK FACTOR; SELF CARE; TRANSITION TO ADULT CARE; COMPLICATION; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PROGNOSIS;

ADULT; CHILD; DYSBIOSIS; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; PROGNOSIS; TRANSITION TO ADULT CARE;

EID: 84955599651     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000602     Document Type: Review

References (196)

1. Franke A, McGovern DPB, Barrett JC, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat Genet. 2010;42:1118-1125.
2. Gjymishka A, Coman RM, Brusko TM, et al. Influence of host immu-noregulatory genes, ER stress and gut microbiota on the shared patho-genesis of inflammatory bowel disease and Type 1 diabetes. Immunotherapy. 2013;5:1357-1366.
3. Sartor RB. Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, and prebiotics. Gastroen-terology. 2004;126:1620-1633.
4. Buffie CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol. 2013;13:790-801.
5. Börnigen D, Morgan XC, Franzosa EA, et al. Functional profiling of the gut microbiome in disease-associated inflammation. Genome Med. 2013;5:65.
6. Burcelin R, Serino M, Chabo C, et al. Metagenome and metabolism: the tissue microbiota hypothesis. Diabetes Obes Metab. 2013;15(suppl 3): 61-70.
7. Mullard A. Microbiology: the inside story. Nature. 2008;453:578-580.
8. Del Chierico F, Vernocchi P, Bonizzi L, et al. Early-life gut microbiota under physiological and pathological conditions: the central role of combined meta-omics-based approaches. J Proteomics. 2012;75:4580-4587.
9. Ventham NT, Kennedy NA, Nimmo ER, et al. Beyond gene discovery in inflammatory bowel disease: the emerging role of epigenetics. Gastro-enterology. 2013;145:293-308.
10. Petrof EO, Claud EC, Gloor GB, et al. Microbial ecosystems therapeutics: a new paradigm in medicine? Benef Microbes. 2013;4:53-65.
11. Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 2007;369:1641-1657.
12. Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology. 2005;129:827-836.
13. Stein J, Hartmann F, Dignass AU. Diagnosis and management of iron deficiency anemia in patients with IBD. Nat Rev Gastroenterol Hepatol. 2010;7:599-610.
14. Liu S, Ren J, Zhao Y, et al. Nonthyroidal illness syndrome: is it far away from Crohn's disease? J Clin Gastroenterol. 2013;47:153-159.
15. Walker AW, Sanderson JD, Churcher C, et al. High-throughput clone library analysis of the mucosa-associated microbiota reveals dysbiosis and differences between inflamed and non-inflamed regions of the intestine in inflammatory bowel disease. BMC Microbiol. 2011;11:7.
16. Kang S, Denman SE, Morrison M, et al. Dysbiosis of fecal microbiota in Crohn's disease patients as revealed by a custom phylogenetic micro-array. Inflamm Bowel Dis. 2010;16:2034-2042.
17. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 2012;491:119-124.
18. Hardenberg G, Steiner TS, Levings MK. Environmental influences on T regulatory cells in inflammatory bowel disease. Semin Immunol. 2011; 23:130-138.
19. Tvede M, Tinggaard M, Helms M. Rectal bacteriotherapy for recurrent Clostridium difficile-associated diarrhoea: results from a case series of 55 patients in Denmark 2000-2012. Clin Microbiol Infect. 2015;21:48-53.
20. Rossen NG, Fuentes S, van der Spek MJ, et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology. 2015;149:110-118.
21. Borody TJ, Paramsothy S, Agrawal G. Fecal microbiota transplantation: indications, methods, evidence, and future directions. Curr Gastroenter-ol Rep. 2013;15:337.
22. Ohkusa T, Sato N. Antibacterial and antimycobacterial treatment for inflammatory bowel disease. J Gastroenterol Hepatol. 2005;20: 340-351.
23. Abraham C, Cho JH. Inflammatory bowel disease. N Engl J Med. 2009; 361:2066-2078.
24. Talley NJ. Scope of the problem of functional digestive disorders. Eur J Surg Suppl. 1998:35-41.
25. Stark D, van Hal S, Marriott D, et al. Irritable bowel syndrome: a review on the role of intestinal protozoa and the importance of their detection and diagnosis. Int J Parasitol. 2007;37:11-20.
26. Paré P, Gray J, Lam S, et al. Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study. Clin Ther. 2006;28:1726-1735; discussion 1710-1711.
27. Grover M, Camilleri M, Smith K, et al. On the fiftieth anniversary. Postinfectious irritable bowel syndrome: mechanisms related to pathogens. Neurogastroenterol Motil. 2014;26:156-167.
28. Fadgyas-Stanculete M, Buga AM, Popa-Wagner A, et al. The relationship between irritable bowel syndrome and psychiatric disorders: from molecular changes to clinical manifestations. J Mol Psychiatry. 2014;2:4.
29. Barreau F, Ferrier L, Fioramonti J, et al. New insights in the etiology and pathophysiology of irritable bowel syndrome: contribution of neonatal stress models. Pediatr Res. 2007;62:240-245.
30. Quigley EM. Bacterial flora in irritable bowel syndrome: role in patho-physiology, implications for management. J Dig Dis. 2007;8:2-7.
31. Si JM, Yu YC, Fan YJ, et al. Intestinal microecology and quality of life in irritable bowel syndrome patients. World J Gastroenterol. 2004;10: 1802-1805.
32. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, et al. The fecal micro-biota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 2007;133:24-33.
33. Tana C, Umesaki Y, Imaoka A, et al. Altered profiles of intestinal micro-biota and organic acids may be the origin of symptoms in irritable bowel syndrome. Neurogastroenterol Motil. 2010;22:512-519, e114-e115.
34. Posserud I, Stotzer PO, Björnsson ES, et al. Small intestinal bacterial overgrowth in patients with irritable bowel syndrome. Gut. 2007;56: 802-808.
35. Yakoob J, Jafri W, Jafri N, et al. Irritable bowel syndrome: in search of an etiology: role of Blastocystis hominis. Am J Trop Med Hyg. 2004;70: 383-385.
36. Giacometti A, Cirioni O, Fiorentini A, et al. Irritable bowel syndrome in patients with Blastocystis hominis infection. Eur J Clin Microbiol Infect Dis. 1999;18:436-439.
37. Windsor JJ, Macfarlane L. Irritable bowel syndrome: the need to exclude Dientamoeba fragilis. Am J Trop Med Hyg. 2005;72:501; author reply 501-502.
38. Krogsgaard LR, Engsbro AL, Stensvold CR, et al. The prevalence of intestinal parasites is not greater among individuals with irritable bowel syndrome: a population-based case-control study. Clin Gastroenterol Hepatol. 2015;13:507-513.e2.
39. Bijkerk CJ, de Wit NJ, Muris JW, et al. Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial. BMJ. 2009;339:b3154.
40. Ducrotté P. Irritable bowel syndrome: current treatment options [in French]. Presse Med. 2007;36:1619-1626.
41. Halmos EP, Power VA, Shepherd SJ, et al. A diet low in FODMAPs reduces symptoms of irritable bowel syndrome. Gastroenterology. 2014; 146:67-75.e5.
42. Mansueto P, Seidita A, D'Alcamo A, et al. Role of FODMAPs in patients with irritable bowel syndrome: a review. Nutr Clin Pract. 2015;30:665-682.
43. Aragon G, Graham DB, Borum M, et al. Probiotic therapy for irritable bowel syndrome. Gastroenterol Hepatol. 2010;6:39-44.
44. Rahimi R, Shams-Ardekani MR, Abdollahi M. A review of the efficacy of traditional Iranian medicine for inflammatory bowel disease. World J Gastroenterol. 2010;16:4504-4514.
45. Simrén M, Barbara G, Flint HJ, et al. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013;62:159-176.
46. Vahedi H, Merat S, Rashidioon A, et al. The effect of fluoxetine in patients with pain and constipation-predominant irritable bowel syndrome: a double-blind randomized-controlled study. Aliment Pharmacol Ther. 2005;22:381-385.
47. Grenham S, Clarke G, Cryan JF, et al. Brain-gut-microbe communication in health and disease. Front Physiol. 2011;2:94.
48. Carabotti M, Scirocco A, Maselli MA, et al. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Ann Gastroenterol. 2015;28:203-209.
49. Holzer P, Farzi A. Neuropeptides and the microbiota-gut-brain axis. Adv Exp Med Biol. 2014;817:195-219.
50. Siragusa S, De Angelis M, Di Cagno R, et al. Synthesis of gamma-aminobutyric acid by lactic acid bacteria isolated from a variety of Italian cheeses. Appl Environ Microbiol. 2007;73:7283-7290.
51. Cryan JF, Dinan TG. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci. 2012;13: 701-712.
52. Mshvildadze M, Neu J. The infant intestinal microbiome: friend or foe? Early Hum Dev. 2010;86(suppl 1):67-71.
53. Adlerberth I, Wold AE. Establishment of the gut microbiota in Western infants. Acta Paediatr. 2009;98:229-238.
54. Bäckhed F, Ley RE, Sonnenburg JL, et al. Host-bacterial mutualism in the human intestine. Science. 2005;307:1915-1920.
55. McFall-Ngai M, Hadfield MG, Bosch TCG, et al. Animals in a bacterial world, a new imperative for the life sciences. Proc Natl Acad Sci USA. 2013;110:3229-3236.
56. Rook GA. Hygiene hypothesis and autoimmune diseases. Clin Rev Allergy Immunol. 2012;42:5-15.
57. Walter J, Ley R. The human gut microbiome: ecology and recent evolutionary changes. Annu Rev Microbiol. 2011;65:411-429.
58. Arumugam M, Raes J, Pelletier E, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-180.
59. Human Microbiome Project Consortium. Structure, function and diversity of the healthy human microbiome. Nature. 2012;486:207-214.
60. Eckburg PB, Bik EM, Bernstein CN, et al. Diversity of the human intestinal microbial flora. Science. 2005;308:1635-1638.
61. Parfrey LW, Walters WA, Knight R. Microbial eukaryotes in the human microbiome: ecology, evolution, and future directions. Front Microbiol. 2011;2:153.
62. De Filippo C, Cavalieri D, Di Paola M, et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci USA. 2010;107:14691-14696.
63. Yatsunenko T, Rey FE, Manary MJ, et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222-227.
64. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380:2095-2128.
65. Manichanh C, Borruel N, Casellas F, et al. The gut microbiota in IBD. Nat Rev Gastroenterol Hepatol. 2012;9:599-608.
66. Hawrelak JA, Myers SP. The causes of intestinal dysbiosis: a review. Altern Med Rev. 2004;9:180-197.
67. Elliott DE, Weinstock JV. Where are we on worms? Curr Opin Gastro-enterol. 2012;28:551-556.
68. Petersen AM, Stensvold CR, Mirsepasi H, et al. Active ulcerative colitis associated with low prevalence of Blastocystis and Dientamoeba fragilis infection. Scand J Gastroenterol. 2013;48:638-639.
69. Scanlan PD, Stensvold CR. Blastocystis: getting to grips with our guileful guest. Trends Parasitol. 2013;29:523-529.
70. Frank DN, St Amand AL, Feldman RA, et al. Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci USA. 2007;104:13780-13785.
71. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147-191.
72. Wong JM, de Souza R, Kendall CWC, et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol. 2006;40:235-243.
73. Tlaskalová-Hogenová H, Stepánková R, Hudcovic T, et al. Commensal bacteria (normal microflora), mucosal immunity and chronic inflammatory and autoimmune diseases. Immunol Lett. 2004;93:97-108.
74. Atarashi K, Tanoue T, Shima T, et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337-341.
75. Ivanov II, Atarashi K, Manel N, et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485-498.
76. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009;9:313-323.
77. Lührs H, Gerke T, Müller JG, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002;37:458-466.
78. Maslowski KM, Vieira AT, Ng A, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282-1286.
79. Cebra JJ, Periwal SB, Lee G, et al. Development and maintenance of the gut-associated lymphoid tissue (GALT): the roles of enteric bacteria and viruses. Dev Immunol. 1998;6:13-18.
80. Bouskra D, Brézillon C, Bérard M, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. Nature. 2008;456:507-510.
81. Haverson K, Rehakova Z, Sinkora J, et al. Immune development in jejunal mucosa after colonization with selected commensal gut bacteria: a study in germ-free pigs. Vet Immunol Immunopathol. 2007;119:243-253.
82. Hapfelmeier S, Lawson MAE, Slack E, et al. Reversible microbial colonization of germ-free mice reveals the dynamics of IgA immune responses. Science. 2010;328:1705-1709.
83. Manco M, Putignani L, Bottazzo GF. Gut microbiota, lipopolysacchar-ides, and innate immunity in the pathogenesis of obesity and cardiovascular risk. Endocr Rev. 2010;31:817-844.
84. Kamada N, Chen GY, Inohara N, et al. Control of pathogens and path-obionts by the gut microbiota. Nat Immunol. 2013;14:685-690.
85. Kleessen B, Blaut M. Modulation of gut mucosal biofilms. Br J Nutr. 2005;93(suppl 1):S35-S40.
86. Hamer HM, Jonkers D, Venema K, et al. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther. 2008;27:104-119.
87. Salminen S, Bouley C, Boutron-Ruault MC, et al. Functional food science and gastrointestinal physiology and function. Br J Nutr. 1998;80 (suppl 1):S147-S171.
88. Stappenbeck TS, Hooper LV, Gordon JI. Developmental regulation of intestinal angiogenesis by indigenous microbes via Paneth cells. Proc Natl Acad Sci USA. 2002;99:15451-15455.
89. Roh YS, Seki E. Toll-like receptors in alcoholic liver disease, nonalcoholic steatohepatitis and carcinogenesis. J Gastroenterol Hepatol 2013;28(suppl 1):38-42.
90. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60:197-209.
91. Moreira APB, Texeira TFS, Ferreira AB, et al. Influence of a high-fat diet on gut microbiota, intestinal permeability and metabolic endotoxae-mia. Br J Nutr. 2012;108:801-809.
92. Lupp C, Robertson ML, Wickham ME, et al. Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe. 2007;2:204.
93. Hardy H, Harris J, Lyon E, et al. Probiotics, prebiotics and immunomo-dulation of gut mucosal defences: homeostasis and immunopathology. Nutrients. 2013;5:1869-1912.
94. Shanahan F, Quigley EM. Manipulation of the microbiota for treatment of IBS and IBD-challenges and controversies. Gastroenterology. 2014; 146:1554-1563.
95. Power SE, O'Toole PW, Stanton C, et al. Intestinal microbiota, diet and health. Br J Nutr. 2014;111:387-402.
96. Younossi ZM, Reyes MJ, Mishra A, et al. Systematic review with metaanalysis: non-alcoholic steatohepatitis-a case for personalised treatment based on pathogenic targets. Aliment Pharmacol Ther. 2014;39:3-14.
97. Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobac-teria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374-2383.
98. Fischbach MA, Sonnenburg JL. Eating for two: how metabolism establishes interspecies interactions in the gut. Cell Host Microbe. 2011;10: 336-347.
99. Walker AW, Ince J, Duncan SH, et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;5:220-230.
100. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105-108.
101. Raffatellu M, George MD, Akiyama Y, et al. Lipocalin-2 resistance confers an advantage to Salmonella enterica serotype Typhimurium for growth and survival in the inflamed intestine. Cell Host Microbe. 2009;5:476-486.
102. Harper RW, Xu C, Eiserich JP, et al. Differential regulation of dual NADPH oxidases/peroxidases, Duox1 and Duox2, by Th1 and Th2 cyto-kines in respiratory tract epithelium. FEBS Lett. 2005;579:4911-4917.
103. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
104. Salzman A, Denenberg AG, Ueta I, et al. Induction and activity of nitric oxide synthase in cultured human intestinal epithelial monolayers. Am J Physiol. 1996;270:G565-G573.
105. Lundberg JO, Hellström PM, Lundberg JM, et al. Greatly increased luminal nitric oxide in ulcerative colitis. Lancet. 1994;344:1673-1674.
106. Gennis RB, Stewart V. Respiration. In Neidhardt FC, Curtiss R III, Ingraham JL, et al (eds). Escherichia coli and Salmonella: Cellular and Molecular Biology. 2nd edition. Washington, DC: ASM Press; 1996:217-261.
107. Sharon I, Morowitz MJ, Thomas BC, et al. Time series community genomics analysis reveals rapid shifts in bacterial species, strains, and phage during infant gut colonization. Genome Res. 2013;23:111-120.
108. Winter SE, Thiennimitr P, Winter MG, et al. Gut inflammation provides a respiratory electron acceptor for Salmonella. Nature. 2010;467:426-429.
109. Arthur JC, Perez-Chanona E, Mühlbauer M, et al. Intestinal inflammation targets cancer-inducing activity of the microbiota. Science. 2012; 338:120-123.
110. Ayres JS, Trinidad NJ, Vance RE. Lethal inflammasome activation by a multidrug-resistant pathobiont upon antibiotic disruption of the micro-biota. Nat Med. 2012;18:799-806.
111. Taur Y, Xavier JB, Lipuma L, et al. Intestinal domination and the risk of bacteremia in patients undergoing allogeneic hematopoietic stem cell transplantation. Clin Infect Dis. 2012;55:905-914.
112. Barnich N, Darfeuille-Michaud A. Adherent-invasive Escherichia coli and Crohn's disease. Curr Opin Gastroenterol. 2007;23:16-20.
113. Kostic AD, Xavier RJ, Gevers D. The microbiome in inflammatory bowel disease: current status and the future ahead. Gastroenterology. 2014;146:1489-1499.
114. Caricilli AM, Castoldi A, Câmara NOS. Intestinal barrier: a gentlemen's agreement between microbiota and immunity. World J Gastrointest Pathophysiol. 2014;5:18-32.
115. Goto Y, Kiyono H. Epithelial barrier: an interface for the cross-communication between gut flora and immune system. Immunol Rev. 2012;245:147-163.
116. Keita AV, Söderholm JD. Barrier dysfunction and bacterial uptake in the follicle-associated epithelium of ileal Crohn's disease. Ann N Y Acad Sci. 2012;1258:125-134.
117. Turner JR. Intestinal mucosal barrier function in health and disease. Nat Rev Immunol. 2009;9:799-809.
118. Ivanov AI, Parkos CA, Nusrat A. Cytoskeletal regulation of epithelial barrier function during inflammation. Am J Pathol. 2010;177:512-524.
119. Odenwald MA, Turner JR. Intestinal permeability defects: is it time to treat? Clin Gastroenterol Hepatol. 2013;11:1075-1083.
120. Bruewer M, Samarin S, Nusrat A. Inflammatory bowel disease and the apical junctional complex. Ann N Y Acad Sci. 2006;1072:242-252.
121. Martínez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut. 2013;62:1160-1168.
122. Suzuki T. Regulation of intestinal epithelial permeability by tight junctions. Cell Mol Life Sci. 2013;70:631-659.
123. Berkes J, Viswanathan VK, Savkovic SD, et al. Intestinal epithelial responses to enteric pathogens: effects on the tight junction barrier, ion transport, and inflammation. Gut. 2003;52:439-451.
124. Hummel S, Veltman K, Cichon C, et al. Differential targeting of the E-Cadherin/P-Catenin complex by gram-positive probiotic lactobacilli improves epithelial barrier function. Appl Environ Microbiol. 2012;78:1140-1147.
125. Dogan A, Wang ZD, Spencer J. E-cadherin expression in intestinal epithelium. J Clin Pathol. 1995;48:143-146.
126. Martinez-Medina M, Denizot J, Dreux N, et al. Western diet induces dysbiosis with increased E coli in CEABAC10 mice, alters host barrier function favouring AIEC colonisation. Gut. 2014;63:116-124.
127. Wilcz-Villega E, McClean S, O'Sullivan M. Reduced E-cadherin expression is associated with abdominal pain and symptom duration in a study of alternating and diarrhea predominant IBS. Neurogastroenterol Motil 2014;26:316-325.
128. Yu LC, Wang JT, Wei SC, et al. Host-microbial interactions and regulation of intestinal epithelial barrier function: from physiology to pathology. World J Gastrointest Pathophysiol. 2012;3:27-43.
129. Leser TD, Mølbak L. Better living through microbial action: the benefits of the mammalian gastrointestinal microbiota on the host. Environ Microbiol. 2009;11:2194-2206.
130. Farhadi A, Banan A, Fields J, et al. Intestinal barrier: an interface between health and disease. J Gastroenterol Hepatol. 2003;18:479-497.
131. Fiorentini C, Fabbri A, Flatau G, et al. Escherichia coli cytotoxic necrotizing factor 1 (CNF1), a toxin that activates the Rho GTPase. J Biol Chem. 1997;272:19532-19537.
132. Simovitch M, Sason H, Cohen S, et al. EspM inhibits pedestal formation by enterohaemorrhagic Escherichia coli and enteropathogenic E. coli and disrupts the architecture of a polarized epithelial monolayer. Cell Microbiol. 2010;12:489-505.
133. Chen WX, Ren LH, Shi RH. Implication of miRNAs for inflammatory bowel disease treatment: systematic review. World J Gastrointest Pathophysiol. 2014;5:63-70.
134. Pekow JR, Kwon JH. MicroRNAs in inflammatory bowel disease. In-flamm Bowel Dis. 2012;18:187-193.
135. Xue X, Cao AT, Cao X, et al. Downregulation of microRNA-107 in intestinal CD11c(+) myeloid cells in response to microbiota and proinflammatory cytokines increases IL-23p19 expression. Eur J Immunol. 2014;44:673-682.
136. Dalmasso G, Nguyen HTT, Yan Y, et al. Microbiota modulate host gene expression via microRNAs. PLoS One. 2011;6:e19293.
137. Lepage P, Häsler R, Spehlmann ME, et al. Twin study indicates loss of interaction between microbiota and mucosa of patients with ulcerative colitis. Gastroenterology. 2011;141:227-236.
138. De Preter V, Bulteel V, Suenaert P, et al. Pouchitis, similar to active ulcerative colitis, is associated with impaired butyrate oxidation by intestinal mucosa. Inflamm Bowel Dis. 2009;15:335-340.
139. Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, et al. Recognition of commensal microflora by Toll-like receptors is required for intestinal homeostasis. Cell. 2004;118:229-241.
140. Bäckhed F, Ding H, Wang T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci USA. 2004; 101:15718-15723.
141. Eckmann L, Stenson WF, Savidge TC, et al. Role of intestinal epithelial cells in the host secretory response to infection by invasive bacteria. Bacterial entry induces epithelial prostaglandin h synthase-2 expression and prostaglandin E2 and F2alpha production. J Clin Invest. 1997;100: 296-309.
142. Hayden MS, Ghosh S. Shared principles in NF-kappaB signaling. Cell. 2008;132:344-362.
143. Schreiber S, Nikolaus S, Hampe J. Activation of nuclear factor kappa B inflammatory bowel disease. Gut. 1998;42:477-484.
144. Nenci A, Becker C, Wullaert A, et al. Epithelial NEMO links innate immunity to chronic intestinal inflammation. Nature. 2007;446:557-561.
145. Zaph C, Troy AE, Taylor BC, et al. Epithelial-cell-intrinsic IKK-beta expression regulates intestinal immune homeostasis. Nature. 2007;446: 552-556.
146. Lakhdari O, Cultrone A, Tap J, et al. Functional metagenomics: a high throughput screening method to decipher microbiota-driven NF-KB modulation in the human gut. PLoS One. 2010;5:pii:e13092.
147. Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut micro-biome correlates with metabolic markers. Nature. 2013;500:541-546.
148. Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585-588.
149. Costello EK, Lauber CL, Hamady M, et al. Bacterial community variation in human body habitats across space and time. Science. 2009;326: 1694-1697.
150. Qin J, Li R, Raes J, et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010;464:59-65.
151. Manichanh C, Rigottier-Gois L, Bonnaud E, et al. Reduced diversity of faecal microbiota in Crohn's disease revealed by a metagenomic approach. Gut. 2006;55:205-211.
152. Balter M. Taking stock of the human microbiome and disease. Science. 2012;336:1246-1247.
153. La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4:371-379.
154. Lord GM, Matarese G, Howard JK, et al. Leptin modulates the T-cell immune response and reverses starvation-induced immunosuppression. Nature. 1998;394:897-901.
155. Bird JJ, Brown DR, Mullen AC, et al. Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998;9:229-237.
156. Peng L, He Z, Chen W, et al. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;61:37-41.
157. Kau AL, Ahern PP, Griffin NW, et al. Human nutrition, the gut micro-biome and the immune system. Nature. 2011;474:327-336.
158. De Preter V, Verbeke K. Metabolomics as a diagnostic tool in gastro-enterology. World J Gastrointest Pharmacol Ther. 2013;4:97-107.
159. Yau Y, Leong RW, Zeng M, et al. Proteomics and metabolomics in inflammatory bowel disease. J Gastroenterol Hepatol. 2013;28:1076-1086.
160. Del Chierico F, Petrucca A, Mortera SL, et al. A metaproteomic pipeline to identify newborn mouse gut phylotypes. J Proteomics. 2014;97:17-26.
161. Juste C, Kreil DP, Beauvallet C, et al. Bacterial protein signals are associated with Crohn's disease. Gut. 2014;63:1566-1577.
162. Hüttenhain R, Soste M, Selevsek N, et al. Reproducible quantification of cancer-associated proteins in body fluids using targeted proteomics. Sci Transl Med. 2012;4:142ra94.
163. Pan S, Chen R, Brand RE, et al. Multiplex targeted proteomic assay for biomarker detection in plasma: a pancreatic cancer biomarker case study. J Proteome Res. 2012;11:1937-1948.
164. Beleites C, Neugebauer U, Bocklitz T, et al. Sample size planning for classification models. Anal Chim Acta. 2013;760:25-33.
165. Figueroa RL, Zeng-Treitler Q, Kandula S, et al. Predicting sample size required for classification performance. BMC Med Inform Decis Mak. 2012;12:8.
166. Capobianco E. Ten challenges for systems medicine. Front Genet. 2012; 3:193.
167. Guo Y, Graber A, McBurney RN, et al. Sample size and statistical power considerations in high-dimensionality data settings: a comparative study of classification algorithms. BMC Bioinformatics. 2010;11:447.
168. Hansen WB, Collins LM. Seven ways to increase power without increasing N. NIDA Res Monogr. 1994;142:184-195.
169. McCrum-Gardner E. Sample size and power calculations made simple. Int J Ther Rehabil. 2010;17:10-14.
170. Mukherjee S, Tamayo P, Rogers S, et al. Estimating dataset size requirements for classifying DNA microarray data. J Comput Biol. 2003;10: 119-142.
171. Suresh K, Chandrashekara S. Sample size estimation and power analysis for clinical research studies. J Hum Reprod Sci. 2012;5:7-13.
172. Öhman L, Törnblom H, Simrén M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol. 2015;12:36-49.
173. Andersen LO, Vedel Nielsen H, Stensvold CR. Waiting for the human intestinal Eukaryotome. ISME J. 2013;7:1253-1255.
174. Lozupone CA, Stombaugh JI, Gordon JI, et al. Diversity, stability and resilience of the human gut microbiota. Nature. 2012;489:220-230.
175. Lagier JC, Million M, Hugon P, et al. Human gut microbiota: repertoire and variations. Front Cell Infect Microbiol. 2012;2:136.
176. Pham NTA, Lawley TD. Pathogens' exploitation of the intestinal food web. Cell Host Microbe. 2014;16:703-705.
177. Molloy MJ, Grainger JR, Bouladoux N, et al. Intraluminal containment of commensal outgrowth in the gut during infection-induced dysbiosis. Cell Host Microbe. 2013;14:318-328.
178. Miquel S, Martín R, Rossi O, et al. Faecalibacterium prausnitzii and human intestinal health. Curr Opin Microbiol. 2013;16:255-261.
179. Vernocchi P, Del Chierico F, Fiocchi AG, et al. Understanding probi-otics' role in allergic children: the clue of gut microbiota profiling. Curr Opin Allergy Clin Immunol. 2015;15:495-503.
180. Knights D, Silverberg MS, Weersma RK, et al. Complex host genetics influence the microbiome in inflammatory bowel disease. Genome Med. 2014;6:107.
181. Vaiopoulou A, Karamanolis G, Psaltopoulou T, et al. Molecular basis of the irritable bowel syndrome. World J Gastroenterol. 2014;20:376-383.
182. Lohmann K, Klein C. Next generation sequencing and the future of genetic diagnosis. Neurotherapeutics. 2014;11:699-707.
183. Merelli I, Pérez-Sánchez H, Gesing S, et al. Managing, analysing, and integrating big data in medical bioinformatics: open problems and future perspectives. Biomed Res Int. 2014;2014:134023.
184. Holmes E, Li JV, Marchesi JR, et al. Gut microbiota composition and activity in relation to host metabolic phenotype and disease risk. Cell Metab. 2012;16:559-564.
185. Dorrestein PC, Mazmanian SK, Knight R. Finding the missing links among metabolites, microbes, and the host. Immunity. 2014;40:824-832.
186. Goldsmith JR, Sartor RB. The role of diet on intestinal microbiota metabolism: downstream impacts on host immune function and health, and therapeutic implications. J Gastroenterol. 2014;49:785-798.
187. Moree WJ, Phelan VV, Wu CH, et al. Interkingdom metabolic transformations captured by microbial imaging mass spectrometry. Proc Natl Acad Sci USA. 2012;109:13811-13816.
188. Traxler MF, Watrous JD, Alexandrov T, et al. Interspecies interactions stimulate diversification of the Streptomyces coelicolor secreted metab-olome. mBio. 2013;4:pii:e00459-13.
189. Yang YL, Xu Y, Straight P, et al. Translating metabolic exchange with imaging mass spectrometry. Nat Chem Biol. 2009;5:885-887.
190. Seyer A, Cantiello M, Bertrand-Michel J, et al. Lipidomic and spatio-temporal imaging of fat by mass spectrometry in mice duodenum during lipid digestion. PLoS One. 2013;8:e58224.
191. Putignani L, Del Chierico F, Petrucca A, et al. The human gut micro-biota: a dynamic interplay with the host from birth to senescence settled during childhood. Pediatr Res. 2014;76:2-10.
192. Klymiuk I, Högenauer C, Halwachs B, et al. A physicians' wish list for the clinical application of intestinal metagenomics. PLoS Med. 2014;11: e1001627.
193. Kinross JM, Darzi AW, Nicholson JK. Gut microbiome-host interactions in health and disease. Genome Med. 2011;3:14.
194. Colombel JF, Grandbastien B, Gower-Rousseau C, et al. Clinical characteristics of Crohn's disease in 72 families. Gastroenterology. 1996; 111:604-607.
195. Spehlmann ME, Begun AZ, Burghardt J, et al. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis. 2008;14:968-976.
196. Halpert AD, Thomas AC, Hu Y, et al. A survey on patient educational needs in irritable bowel syndrome and attitudes toward participation in clinical research. J Clin Gastroenterol. 2006;40:37-43.